Search

Your search keyword '"Cusi, Kenneth"' showing total 1,068 results
Start Over Author "Cusi, Kenneth"
1,068 results on '"Cusi, Kenneth"'

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Author

Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D, Narro, Graciela E Castro, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart G, Korenjak, Marko, Kowdley, Kris V, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth E, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N, and group, NAFLD Nomenclature consensus

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Digestive Diseases, Clinical Research, Hepatitis, Chronic Liver Disease and Cirrhosis, Substance Misuse, Oral and gastrointestinal, Good Health and Well Being, Female, Male, Humans, Non-alcoholic Fatty Liver Disease, Delphi Technique, Ethanol, Consensus, Hepatomegaly, NAFLD Nomenclature consensus group, ALD, Delphi, MASH, MASLD, Met-ALD, NAFLD, alcohol, metabolic, nomenclature, stigma, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Abstract

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and non-stigmatising, and can improve awareness and patient identification.

Published
2023

2. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

Author

Rinella, Mary, Lazarus, Jeffrey, Ratziu, Vlad, Francque, Sven, Sanyal, Arun, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal, Anstee, Quentin, Arab, Juan, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher, Castro Narro, Graciela, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia, Harrison, Stephen, Kim, Seung, Koot, Bart, Korenjak, Marko, Kowdley, Kris, Lacaille, Florence, Powell, Elisabeth, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram, Sookoian, Silvia, Spearman, C, Tiniakos, Dina, Valenti, Luca, Vos, Miriam, Wong, Vincent, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip, Mitchell-Thain, Robert, Morgan, Timothy, and Loomba, Rohit

Subjects
Male, Female, Humans, Non-alcoholic Fatty Liver Disease, Delphi Technique, Hepatomegaly, Surveys and Questionnaires
Abstract

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms nonalcoholic and fatty were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification.

Published
2023

3. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

Author

Younossi, Zobair M, AlQahtani, Saleh A, Alswat, Khalid, Yilmaz, Yusuf, Keklikkiran, Caglayan, Funuyet-Salas, Jesús, Romero-Gómez, Manuel, Fan, Jian-Gao, Zheng, Ming-Hua, El-Kassas, Mohamed, Castera, Laurent, Liu, Chun-Jen, Wong, Vincent Wai-Sun, Zelber-Sagi, Shira, Allen, Alina M, Lam, Brian, Treeprasertsuk, Sombat, Hameed, Saeed, Takahashi, Hirokazu, Kawaguchi, Takumi, Schattenberg, Jörn M, Duseja, Ajay, Newsome, Phil, Francque, Sven, Spearman, C Wendy, Fernández, Marlen I Castellanos, Burra, Patrizia, Roberts, Stuart K, Chan, Wah-Kheong, Arrese, Marco, Silva, Marcelo, Rinella, Mary, Singal, Ashwani K, Gordon, Stuart, Fuchs, Michael, Alkhouri, Naim, Cusi, Kenneth, Loomba, Rohit, Ranagan, Jane, Eskridge, Wayne, Kautz, Achim, Ong, Janus P, Kugelmas, Marcelo, Eguchi, Yuichiro, Diago, Moises, Yu, Ming-Lung, Gerber, Lynn, Fornaresio, Lisa, Nader, Fatema, Henry, Linda, Racila, Andrei, Golabi, Pegah, Stepanova, Maria, Carrieri, Patrizia, Lazarus, Jeffrey V, and Council, the Global NASH

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Hepatitis, Health Services, Clinical Research, Prevention, Good Health and Well Being, Global NASH Council, MASH, MASLD, SLD, communication, discrimination, fatty liver, metabolic, patient-reported outcomes, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background & aimsPatients with fatty liver disease may experience stigma from the disease or comorbidities. In this cross-sectional study, we aimed to understand stigma among patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) and healthcare providers.MethodsMembers of the Global NASH Council created two surveys about experiences/attitudes toward NAFLD and related diagnostic terms: a 68-item patient and a 41-item provider survey.ResultsSurveys were completed by 1,976 patients with NAFLD across 23 countries (51% Middle East/North Africa [MENA], 19% Europe, 17% USA, 8% Southeast Asia, 5% South Asia) and 825 healthcare providers (67% gastroenterologists/hepatologists) across 25 countries (39% MENA, 28% Southeast Asia, 22% USA, 6% South Asia, 3% Europe). Of all patients, 48% ever disclosed having NAFLD/NASH to family/friends; the most commonly used term was "fatty liver" (88% at least sometimes); "metabolic disease" or "MAFLD" were rarely used (never by >84%). Regarding various perceptions of diagnostic terms by patients, there were no substantial differences between "NAFLD", "fatty liver disease (FLD)", "NASH", or "MAFLD". The most popular response was being neither comfortable nor uncomfortable with either term (56%-71%), with slightly greater discomfort with "FLD" among the US and South Asian patients (47-52% uncomfortable). Although 26% of patients reported stigma related to overweight/obesity, only 8% reported a history of stigmatization or discrimination due to NAFLD. Among providers, 38% believed that the term "fatty" was stigmatizing, while 34% believed that "nonalcoholic" was stigmatizing, more commonly in MENA (43%); 42% providers (gastroenterologists/hepatologists 45% vs. 37% other specialties, p = 0.03) believed that the name change to metabolic dysfunction-associated steatotic liver disease (or MASLD) might reduce stigma. Regarding the new nomenclature, the percentage of providers reporting "steatotic liver disease" as stigmatizing was low (14%).ConclusionsThe perception of NAFLD stigma varies among patients, providers, geographic locations and sub-specialties.Impact and implicationsOver the past decades, efforts have been made to change the nomenclature of nonalcoholic fatty liver disease (NAFLD) to better align with its underlying pathogenetic pathways and remove any potential stigma associated with the name. Given the paucity of data related to stigma in NAFLD, we undertook this global comprehensive survey to assess stigma in NAFLD among patients and providers from around the world. We found there is a disconnect between physicians and patients related to stigma and related nomenclature. With this knowledge, educational programs can be developed to better target stigma in NAFLD among all stakeholders and to provide a better opportunity for the new nomenclature to address the issues of stigma.

Published
2023

4. THU-453 Stigma in NAFLD and NASH: a global survey of patients and providers

Author

Younossi, Zobair, Yılmaz, Yusuf, Fan, Jian-Gao, Wong, Vincent Wai-Sun, Kassas, Mohamed El, Zelber-Sagi, Shira, Allen, Alina, Rinella, Mary, Singal, Ashwani, Gordon, Stuart C, Fuchs, Michael, Eskridge, Wayne, Alkhouri, Naim, Alswat, Khalid, Takahashi, Hirokazu, Kawaguchi, Takumi, Ranagan, Jane, Zheng, Ming-Hua, Duseja, Ajay Kumar, Burra, Patrizia, Patrizia, Carrieri, Arrese, Marco, Kautz, Achim, Ong, Janus, Castera, Laurent, Francque, Sven, Kugelmas, Marcelo, Eguchi, Yuichiro, Treeprasertsuk, Sombat, Fernández, Marlen Ivon Castellanos, Gomez, Manuel Romero, Newsome, Philip N, Cusi, Kenneth, Loomba, Rohit, Schattenberg, Jörn, Yu, Ming-Lung, Diago, Moises, Gerber, Lynn, Lam, Brian, Fornaresio, Lisa, Nader, Fatema, Henry, Linda, Racila, Andrei, Golabi, Pegah, Stepanova, Maria, Alqahtani, Saleh, and Lazarus, Jeffrey

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Published
2023

6. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice

Author

Lazarus, Jeffrey V, Castera, Laurent, Mark, Henry E, Allen, Alina M, Adams, Leon A, Anstee, Quentin M, Arrese, Marco, Alqahtani, Saleh A, Bugianesi, Elisabetta, Colombo, Massimo, Cusi, Kenneth, Hagström, Hannes, Loomba, Rohit, Romero-Gómez, Manuel, Schattenberg, Jörn M, Thiele, Maja, Valenti, Luca, Wong, Vincent Wai-Sun, Yilmaz, Yusuf, Younossi, Zobair M, Francque, Sven M, and Tsochatzis, Emmanuel A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Chronic Liver Disease and Cirrhosis, Liver Disease, Digestive Diseases, Good Health and Well Being, Hepatology, NAFLD, NITs, FIB-4, Elastography, NFS, FIB-4, Fibrosis-4, NAFLD, Non-alcoholic fatty liver disease, NFS, NAFLD fibrosis score, NIT, Non-invasive test, Clinical sciences
Abstract

Background & aimsNon-invasive tests (NITs) offer a practical solution for advanced fibrosis identification in non-alcoholic fatty liver disease (NAFLD). Despite increasing implementation, their use is not standardised, which can lead to inconsistent interpretation and risk stratification. We aimed to assess the types of NITs and the corresponding cut-offs used in a range of healthcare settings.MethodsA survey was distributed to a convenience sample of liver health experts who participated in a global NAFLD consensus statement. Respondents provided information on the NITs used in their clinic with the corresponding cut-offs and those used in established care pathways in their areas.ResultsThere were 35 respondents from 24 countries, 89% of whom practised in tertiary level settings. A total of 14 different NITs were used, and each respondent reported using at least one (median = 3). Of the respondents, 80% reported using FIB-4 and liver stiffness by vibration-controlled transient elastography (Fibroscan®), followed by the NAFLD fibrosis score (49%). For FIB-4, 71% of respondents used a low cut-off of 7.5 to >20 kPa, respectively).ConclusionsThe cut-offs used for the same NITs for NAFLD risk stratification vary between clinicians. As cut-offs impact test performance, these findings underscore the heterogeneity in risk-assessment and support the importance of establishing consistent guidelines on the standardised use of NITs in NAFLD management.Lay summaryOwing to the high prevalence of non-alcoholic fatty liver disease (NAFLD) in the general population it is important to identify those who have more advanced stages of liver fibrosis, so that they can be properly treated. Non-invasive tests (NITs) provide a practical way to assess fibrosis risk in patients. However, we found that the cut-offs used for the same NITs vary between clinicians. As cut-offs impact test performance, these findings highlight the importance of establishing consistent guidelines on the standardised use of NITs to optimise clinical management of NAFLD.

Published
2023

7. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

Author

Martínez‐Arranz, Ibon, Bruzzone, Chiara, Noureddin, Mazen, Gil‐Redondo, Ruben, Mincholé, Itziar, Bizkarguenaga, Maider, Arretxe, Enara, Iruarrizaga‐Lejarreta, Marta, Fernández‐Ramos, David, Lopitz‐Otsoa, Fernando, Mayo, Rebeca, Embade, Nieves, Newberry, Elizabeth, Mittendorf, Bettina, Izquierdo‐Sánchez, Laura, Smid, Vaclav, Arnold, Jorge, Iruzubieta, Paula, Castaño, Ylenia Pérez, Krawczyk, Marcin, Marigorta, Urko M, Morrison, Martine C, Kleemann, Robert, Martín‐Duce, Antonio, Hayardeny, Liat, Vitek, Libor, Bruha, Radan, de la Fuente, Rocío Aller, Crespo, Javier, Romero‐Gomez, Manuel, Banales, Jesus M, Arrese, Marco, Cusi, Kenneth, Bugianesi, Elisabetta, Klein, Samuel, Lu, Shelly C, Anstee, Quentin M, Millet, Oscar, Davidson, Nicholas O, Alonso, Cristina, and Mato, José M

Subjects
Medical Biochemistry and Metabolomics, Biomedical and Clinical Sciences, Heart Disease, Cardiovascular, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Genetics, Liver Disease, Atherosclerosis, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being, Animals, Apolipoproteins B, Cardiovascular Diseases, Cholesterol, VLDL, Heart Disease Risk Factors, Lipoproteins, VLDL, Liver, Mice, Non-alcoholic Fatty Liver Disease, Phospholipases, Risk Factors, Triglycerides, Clinical Sciences, Immunology, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background and aimsWe previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors.Approach and resultsWe analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL-apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6 , and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A.ConclusionsMetabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification.

Published
2022

9. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease

Author

Younossi, Zobair M., AlQahtani, Saleh A., Funuyet-Salas, Jesús, Romero-Gómez, Manuel, Yilmaz, Yusuf, Keklikkiran, Caglayan, Alswat, Khalid, Yu, Ming-Lung, Liu, Chun-Jen, Fan, Jian-Gao, Zheng, Ming-Hua, Burra, Patrizia, Francque, Sven M., Castera, Laurent, Schattenberg, Jörn M., Newsome, Philip N., Allen, Alina M., El-Kassas, Mohamed, Treeprasertsuk, Sombat, Hameed, Saeed, Wai-Sun Wong, Vincent, Zelber-Sagi, Shira, Takahashi, Hirokazu, Kawaguchi, Takumi, Castellanos Fernández, Marlen I., Duseja, Ajay, Arrese, Marco, Rinella, Mary, Singal, Ashwani K., Gordon, Stuart C., Fuchs, Michael, Eskridge, Wayne, Alkhouri, Naim, Cusi, Kenneth, Loomba, Rohit, Ranagan, Jane, Kautz, Achim, Ong, Janus P., Kugelmas, Marcelo, Eguchi, Yuichiro, Diago, Moises, Gerber, Lynn, Lam, Brian, Fornaresio, Lisa, Nader, Fatema, Spearman, C. Wendy, Roberts, Stuart K., Chan, Wah-Kheong, Silva, Marcelo, Racila, Andrei, Golabi, Pegah, Ananchuensook, Prooksa, Henry, Linda, Stepanova, Maria, Carrieri, Patrizia, and Lazarus, Jeffrey V.

Published
2024
Full Text
View/download PDF

11. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

Author

Younossi, Zobair M., Alqahtani, Saleh A., Alswat, Khalid, Yilmaz, Yusuf, Keklikkiran, Caglayan, Funuyet-Salas, Jesús, Romero-Gómez, Manuel, Fan, Jian-Gao, Zheng, Ming-Hua, El-Kassas, Mohamed, Castera, Laurent, Liu, Chun-Jen, Wai-Sun Wong, Vincent, Zelber-Sagi, Shira, Allen, Alina M., Lam, Brian, Treeprasertsuk, Sombat, Hameed, Saeed, Takahashi, Hirokazu, Kawaguchi, Takumi, Schattenberg, Jörn M., Duseja, Ajay, Newsome, Phil N., Francque, Sven, Spearman, C. Wendy, Castellanos Fernández, Marlen I., Burra, Patrizia, Roberts, Stuart K., Chan, Wah-Kheong, Arrese, Marco, Silva, Marcelo, Rinella, Mary, Singal, Ashwani K., Gordon, Stuart, Fuchs, Michael, Alkhouri, Naim, Cusi, Kenneth, Loomba, Rohit, Ranagan, Jane, Eskridge, Wayne, Kautz, Achim, Ong, Janus P., Kugelmas, Marcelo, Eguchi, Yuichiro, Diago, Moises, Yu, Ming-Lung, Gerber, Lynn, Fornaresio, Lisa, Nader, Fatema, Henry, Linda, Racila, Andrei, Golabi, Pegah, Stepanova, Maria, Carrieri, Patrizia, and Lazarus, Jeffrey V.

Published
2024
Full Text
View/download PDF

12. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease

Author

Kanwal, Fasiha, Shubrook, Jay H, Adams, Leon A, Pfotenhauer, Kim, Wai-Sun Wong, Vincent, Wright, Eugene, Abdelmalek, Manal F, Harrison, Stephen A, Loomba, Rohit, Mantzoros, Christos S, Bugianesi, Elisabetta, Eckel, Robert H, Kaplan, Lee M, El-Serag, Hashem B, and Cusi, Kenneth

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Nutrition and Dietetics, Chronic Liver Disease and Cirrhosis, Clinical Research, Digestive Diseases, Prevention, Hepatitis, Health Services, Liver Disease, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, 7.3 Management and decision making, Oral and gastrointestinal, Cardiovascular, Good Health and Well Being, Clinical Decision-Making, Consensus, Critical Pathways, Decision Support Techniques, Evidence-Based Medicine, Gastroenterology, Humans, Non-alcoholic Fatty Liver Disease, Predictive Value of Tests, Risk Assessment, Risk Factors, Treatment Outcome, Nonalcoholic Fatty Liver Disease, NAFLD, Nonalcoholic Steatohepatitis, NASH, Clinical Care Pathway, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.gastro.org. Scan this QR code to be taken directly to the website.Nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common, currently affecting approximately 37% of US adults. NAFLD is most often managed in primary care or endocrine clinics, where clinicians must determine which patients might benefit from secondary care to address hepatic manifestations, comorbid metabolic traits, and cardiovascular risks of the disease. Because NAFLD is largely asymptomatic, and because optimal timing of treatment depends on accurate staging of fibrosis risk, screening at the primary care level is critical, together with consistent, timely, evidence-based, widely accessible, and testable management processes. To achieve these goals, the American Gastroenterological Association assembled a multidisciplinary panel of experts to develop a Clinical Care Pathway providing explicit guidance on the screening, diagnosis, and treatment of NAFLD. This article describes the NAFLD Clinical Care Pathway they developed and provides a rationale supporting proposed steps to assist clinicians in diagnosing and managing NAFLD with clinically significant fibrosis (stage F2-F4) based on the best available evidence. This Pathway is intended to be applicable in any setting where care for patients with NAFLD is provided, including primary care, endocrine, obesity medicine, and gastroenterology practices.

Published
2021

14. Implementation of a liver health check in people with type 2 diabetes

Author

Abeysekera, Kushala W M, Valenti, Luca, Younossi, Zobair, Dillon, John F, Allen, Alina M, Noureddin, Mazen, Rinella, Mary E, Tacke, Frank, Francque, Sven, Ginès, Pere, Thiele, Maja, Newsome, Philip N, Guha, Indra Neil, Eslam, Mohammed, Schattenberg, Jörn M, Alqahtani, Saleh A, Arrese, Marco, Berzigotti, Annalisa, Holleboom, Adriaan G, Caussy, Cyrielle, Cusi, Kenneth, Roden, Michael, Hagström, Hannes, Wong, Vincent Wai-Sun, Mallet, Vincent, Castera, Laurent, Lazarus, Jeffrey V, and Tsochatzis, Emmanuel A

Published
2024
Full Text
View/download PDF

15. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Author

Rinella, Mary E., Lazarus, Jeffrey V., Ratziu, Vlad, Francque, Sven M., Sanyal, Arun J., Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F., Anstee, Quentin M., Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D., Narro, Graciela E. Castro, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R., Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D., Harrison, Stephen A., Kim, Seung Up, Koot, Bart G., Korenjak, Marko, Kowdley, Kris V., Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R., Powell, Elisabeth E., Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C., Spearman, C. Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B., Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, and Newsome, Philip N.

Published
2024
Full Text
View/download PDF

17. Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study

Author

Barritt, A Sidney, Watkins, Stephanie, Gitlin, Norman, Klein, Samuel, Lok, Anna S, Loomba, Rohit, Schoen, Cheryl, Reddy, K Rajender, Trinh, Huy Ngoc, Mospan, Andrea R, Vos, Miriam B, Weiss, L Michael, Cusi, Kenneth, Neuschwander‐Tetri, Brent A, and Sanyal, Arun J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Hepatitis, Clinical Research, Good Health and Well Being, Clinical sciences
Abstract

Much of the current data on nonalcoholic fatty liver disease (NAFLD) are derived from biopsy-based studies that may introduce ascertainment and selection bias. Selection of patients for liver biopsy has implications for clinical practice and the reported epidemiology of NAFLD. The aim of this study was to determine patient factors predictive of histologic versus empiric clinical diagnosis of NAFLD in real-world practice. Adults from TARGET-NASH were included in this study. Descriptive statistics are provided for the cohort and compare the characteristics of histologic NAFLD versus patients with clinically diagnosed NAFLD, followed by logistic regression and machine-learning models to describe predictors of liver biopsy. The records of 3,474 subjects were analyzed; median age was 59 years, 59% were female, 75% were White, and median body mass index was 32 kg/m2. Using histologic and/or clinical criteria, a diagnosis of nonalcoholic steatohepatitis was made in 37%, and cirrhosis in 33%. Comorbid conditions included cardiovascular disease (19%), mental health diagnoses (49%), and osteoarthritis (10%). Predictors of a biopsy diagnosis included White race, female sex, diabetes, and elevated alanine aminotransferase (ALT). ALT increased the odds of liver biopsy by 14% per 10-point rise. Machine-learning analyses showed non-White patients with ALT

Published
2021

19. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort

Author

Abdelmalek, Manal, Aguilar, Humberto, Ahmed, Aijaz, Allen, Alina, Barlow, Sarah, Barritt, Sid, Bernstein, David, Bhamidimarri, Kaylan, Billings, Liana, Brown, Kyle, Brown, Robert, Corbin, Karen, Cusi, Kenneth, deLemos, Andrew, Emerick, Karan, Firpi-Morell, Roberto, Ghali, Maged Adel, Henry, Zachary, Jackson, Whitney, Janardhan, Sujit, Kabbany, Mohammad, Kemmer, Nyingi, Koch, David, Kupec, Justin, Landis, Charles, Lawrence, Mary Katherine, Levy, Cynthia, Lidofsky, Steven, Lok, Anna, Luketic, Velimir, Martinez, Enrique, McClain, Craig, McKiernan, Patrick, Mitchell, Ellen, Noureddin, Mazen, Palle, Sirish, Pham, Yen, Pound, David, Reddy, Rajender, Regenstein, Fredric, Rinella, Mary, Rochling, Fedja, Rudolph, Bryan, Rustgi, Vinod, Said, Adnan, Samala, Niharika, Sarkar, Souvik, Sherman, Kenneth, Shiffman, Mitchell, Smith, Coleman, Taunk, Jawahar, Tetri, Brent, Thuluvath, Paul, Trinh, Huy, Verna, Elizabeth, Vos, Miriam, Weiss, L. Michael, Wong, Mark, Wyne, Kathleen, Xanthakos, Stavra, Sanyal, Arun J., Munoz, Breda, Barritt, A. Sidney, IV, Muthiah, Mark, Mospan, Andrea R., Reddy, K. Rajender, Thuluvath, Paul J., Bhamidimarri, Kalyan Ram, and Fried, Michael W.

Published
2023
Full Text
View/download PDF

20. A global research priority agenda to advance public health responses to fatty liver disease

Author

Lazarus, Jeffrey V., Mark, Henry E., Allen, Alina M., Arab, Juan Pablo, Carrieri, Patrizia, Noureddin, Mazen, Alazawi, William, Alkhouri, Naim, Alqahtani, Saleh A., Arrese, Marco, Bataller, Ramon, Berg, Thomas, Brennan, Paul N., Burra, Patrizia, Castro-Narro, Graciela E., Cortez-Pinto, Helena, Cusi, Kenneth, Dedes, Nikos, Duseja, Ajay, Francque, Sven M., Hagström, Hannes, Huang, Terry T-K., Wajcman, Dana Ivancovsky, Kautz, Achim, Kopka, Christopher J., Krag, Aleksander, Miller, Veronica, Newsome, Philip N., Rinella, Mary E., Romero, Diana, Sarin, Shiv Kumar, Silva, Marcelo, Spearman, C. Wendy, Tsochatzis, Emmanuel A., Valenti, Luca, Villota-Rivas, Marcela, Zelber-Sagi, Shira, Schattenberg, Jörn M., Wong, Vincent Wai-Sun, Younossi, Zobair M., Aberg, Fredrik, Adams, Leon, Al-Naamani, Khalid, Albadawy, Reda M., Alexa, Zinaida, Allison, Michael, Alnaser, Faisal A., Alswat, Khalid, Alvares-da-Silva, Mario Reis, Alvaro, Domenico, Alves-Bezerra, Michele, Andrade, Raul J., Anstee, Quentin M., Awuku, Yaw Asante, Baatarkhuu, Oidov, Baffy, Gyorgy, Bakieva, Shokhista, Bansal, Meena B., Barouki, Robert, Batterham, Rachel L., Behling, Cynthia, Belfort-DeAguiar, Renata, Berzigotti, Annalisa, Betel, Michael, Bianco, Cristiana, Bosi, Emanuele, Boursier, Jerome, Brunt, Elizabeth M., Bugianesi, Elisabetta, Byrne, Christopher J., Cabrera Cabrejos, Maria Cecilia, Caldwell, Stephen, Carr, Rotonya, Castellanos Fernández, Marlen Ivón, Castera, Laurent, Castillo-López, Maria Gabriela, Caussy, Cyrielle, Cerda-Reyes, Eira, Ceriello, Antonio, Chan, Wah- Kheong, Chang, Yoosoo, Charatcharoenwitthaya, Phunchai, Chavez-Tapia, Norberto, Chung, Raymond T., Colombo, Massimo, Coppell, Kirsten, Cotrim, Helma P., Craxi, Antonio, Crespo, Javier, Dassanayake, Anuradha, Davidson, Nicholas O., De Knegt, Robert, de Ledinghen, Victor, Demir, Münevver, Desalegn, Hailemichael, Diago, Moises, Dillon, John F., Dimmig, Bruce, Dirac, M. Ashworth, Dirchwolf, Melisa, Dufour, Jean-François, Dvorak, Karel, Ekstedt, Mattias, El-Kassas, Mohamed, Elsanousi, Osama M., Elsharkawy, Ahmed M., Elwakil, Reda, Eskridge, Wayne, Eslam, Mohammed, Esmat, Gamal, Fan, Jian- Gao, Ferraz, Maria Lucia, Flisiak, Robert, Fortin, Davide, Fouad, Yasser, Freidman, Scott L., Fuchs, Michael, Gadano, Adrian, Gastaldelli, Amalia, Geerts, Anja, Geier, Andreas, George, Jacob, Gerber, Lynn H., Ghazinyan, Hasmik, Gheorghe, Liana, Kile, Denise Giangola, Girala, Marcos, Boon Bee, George Goh, Goossens, Nicolas, Graupera, Isabel, Grønbæk, Henning, Hamid, Saeed, Hebditch, Vanessa, Henry, Zachary, Hickman, Ingrid J., Hobbs, L. Ansley, Hocking, Samantha L., Hofmann, Wolf Peter, Idilman, Ramazan, Iruzubieta, Paula, Isaacs, Scott, Isakov, Vasily A., Ismail, Mona H., Jamal, Mohammad H., Jarvis, Helen, Jepsen, Peter, Jornayvaz, François, Sudhamshu, K.C., Kakizaki, Satoru, Karpen, Saul, Kawaguchi, Takumi, Keating, Shelley E., Khader, Yousef, Kim, Seung Up, Kim, Won, Kleiner, David E., Koek, Ger, Joseph Komas, Narcisse Patrice, Kondili, Loreta A., Koot, Bart G., Korenjak, Marko, Kotsiliti, Eleni, Koulla, Yiannoula, Kugelmas, Carina, Kugelmas, Marcelo, Labidi, Asma, Lange, Naomi F., Lavine, Joel E., Lazo, Mariana, Leite, Nathalie, Lin, Han-Chieh, Lkhagvaa, Undram, Long, Michelle T., Lopez-Jaramillo, Patricio, Lozano, Adelina, Macedo, Maria Paula, Malekzadeh, Reza, Marchesini, Giulio, Marciano, Sebastian, Martinez, Kim, Martínez Vázquez, Sophia E., Mateva, Lyudmila, Mato, José M., Nlombi, Charles Mbendi, McCary, Alexis Gorden, McIntyre, Jeff, McKee, Martin, Mendive, Juan M., Mikolasevic, Ivana, Miller, Pamela S., Milovanovic, Tamara, Milton, Terri, Moreno-Alcantar, Rosalba, Morgan, Timothy R., Motala, Ayesha, Muris, Jean, Musso, Carla, Nava-González, Edna J., Negro, Francesco, Nersesov, Alexander V., Neuschwander-Tetri, Brent A., Nikolova, Dafina, Norris, Suzanne, Novak, Katja, Ocama, Ponsiano, Ong, Janus P., Ong-Go, Arlinking, Onyekwere, Charles, Padilla, Martin, Pais, Raluca, Pan, Calvin, Panduro, Arturo, Panigrahi, Manas K., Papatheodoridis, Georgios, Paruk, Imran, Patel, Keyur, Gonçalves, Carlos Penha, Figueroa, Marlene Pérez, Pérez-Escobar, Juanita, Pericàs, Juan M., Perseghin, Gianluca, Pessoa, Mário Guimarães, Petta, Salvatore, Marques Souza de Oliveira, Claudia Pinto, Prabhakaran, Dorairaj, Pyrsopoulous, Nikolaos, Rabiee, Atoosa, Ramji, Alnoor, Ratziu, Vlad, Ravendhran, Natarajan, Ray, Katrina, Roden, Michael, Romeo, Stefano, Romero-Gómez, Manuel, Rotman, Yaron, Rouabhia, Samir, Rowe, Ian A., Sadirova, Shakhlo, Alkhatry, Maryam Salem, Salupere, Riina, Satapathy, Sanjaya K., Schwimmer, Jeffrey B., Sebastiani, Giada, Seim, Lynn, Seki, Yosuke, Serme, Abdel Karim, Shapiro, David, Sharvadze, Lali, Shaw, Jonathan E., Shawa, Isaac Thom, Shenoy, Thrivikrama, Shibolet, Oren, Shimakawa, Yusuke, Shubrook, Jay H., Singh, Shivaram Prasad, Sinkala, Edford, Skladany, Lubomir, Skrypnyk, Igor, Song, Myeong Jun, Sookoian, Silvia, Sridharan, Kannan, Stefan, Norbert, Stine, Jonathan G., Stratakis, Nikolaos, Sheriff, Dhastagir Sultan, Sundaram, Shikha S., Svegliati-Baroni, Gianluca, Swain, Mark G., Tacke, Frank, Taheri, Shahrad, Tan, Soek-Siam, Tapper, Elliot B., Targher, Giovanni, Tcaciuc, Eugen, Thiele, Maja, Tiniakos, Dina, Tolmane, Ieva, Torre, Aldo, Torres, Esther A., Treeprasertsuk, Sombat, Trenell, Michael, Turcan, Svetlana, Turcanu, Adela, Valantinas, Jonas, van Kleef, Laurens A., Velarde Ruiz Velasco, Jose Antonio, Vesterhus, Mette, Vilar-Gomez, Eduardo, Waked, Imam, Wattacheril, Julia, Wedemeyer, Heiner, Wilkins, Fonda, Willemse, José, Wong, Robert J., Yilmaz, Yusuf, Yki-Järvinen, Hannele, Yu, Ming-Lung, Yumuk, Volkan, Zeybel, Müjdat, Zheng, Kenneth I., Zheng, Ming-Hua, and Huang, Terry T.-K.

Published
2023
Full Text
View/download PDF

22. Research Priorities for Precision Medicine in NAFLD

Author

Iruzubieta, Paula, Bataller, Ramon, Arias-Loste, María Teresa, Arrese, Marco, Calleja, José Luis, Castro-Narro, Graciela, Cusi, Kenneth, Dillon, John F., Martínez-Chantar, María Luz, Mateo, Miguel, Pérez, Antonio, Rinella, Mary E., Romero-Gómez, Manuel, Schattenberg, Jörn M., Zelber-Sagi, Shira, Crespo, Javier, and Lazarus, Jeffrey V.

Published
2023
Full Text
View/download PDF

25. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis

Author

Mak, Lung-Yi, Gane, Ed, Schwabe, Christian, Yoon, Ki Tae, Heo, Jeong, Scott, Russell, Lee, Jeong-Hoon, Lee, Jung Il, Kweon, Young Oh, Weltman, Martin, Harrison, Stephen A., Neuschwander-Tetri, Brent A., Cusi, Kenneth, Loomba, Rohit, Given, Bruce D., Christianson, Dawn R., Garcia-Medel, Eric, Yi, Min, Hamilton, James, and Yuen, Man-Fung

Published
2023
Full Text
View/download PDF

26. Measuring NAFLD models of care

Author

Allen, Alina M., Younossi, Zobair M., Tsochatzis, Emmanuel A., Alazawi, William, Zelber-Sagi, Shira, Arab, Juan Pablo, Cusi, Kenneth, and Lazarus, Jeffrey V.

Published
2023
Full Text
View/download PDF

28. Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).

Author

Noureddin, Mazen, Truong, Emily, Mayo, Rebeca, Martínez-Arranz, Ibon, Mincholé, Itziar, Banales, Jesus M., Arrese, Marco, Cusi, Kenneth, Arias-Loste, María Teresa, Bruha, Radan, Romero-Gómez, Manuel, Iruzubieta, Paula, Aller, Rocio, Ampuero, Javier, Calleja, José Luis, Ibañez-Samaniego, Luis, Aspichueta, Patricia, Marín-Duce, Antonio, Kushner, Tatyana, and Ortiz, Pablo

Published
2025
Full Text
View/download PDF

30. Summary of Revisions: Standards of Care in Diabetes—2025.

Author

ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Bajaj, Mandeep, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Callaghan, Brian C., Cusi, Kenneth, Das, Sandeep R., Ebekozien, Osagie, Echouffo-Tcheugui, Justin B., Eichorst, Barbara, Ekhlaspour, Laya, Fleming, Talya K., Frykberg, Robert G., Gaglia, Jason L., Galindo, Rodolfo J., and Garg, Rajesh

Subjects
MEDICAL personnel, MEDICAL care, MATURITY onset diabetes of the young, TYPE 2 diabetes, GESTATIONAL diabetes, PRAGMATICS, INTERPROFESSIONAL education
Abstract

The 2025 "Standards of Care in Diabetes" published in Diabetes Care by the American Diabetes Association reflects the evolving landscape of diabetes care, incorporating person-first language and inclusive terminology. Endorsements from various medical societies were received for different sections, emphasizing the importance of comprehensive care. The document details revisions across multiple sections, including recommendations for populations at risk, diagnosis and classification of diabetes, prevention strategies, and management of comorbidities, reflecting the latest evidence-based practices in diabetes care. [Extracted from the article]

Published
2025
Full Text
View/download PDF

31. Introduction and Methodology: Standards of Care in Diabetes—2025.

Author

ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Bajaj, Mandeep, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Callaghan, Brian C., Cusi, Kenneth, Das, Sandeep R., Ebekozien, Osagie, Echouffo-Tcheugui, Justin B., Eichorst, Barbara, Ekhlaspour, Laya, Fleming, Talya K., Frykberg, Robert G., Gaglia, Jason L., Galindo, Rodolfo J., and Garg, Rajesh

Subjects
MEDICAL personnel, GESTATIONAL diabetes, DIABETIC foot, TYPE 1 diabetes, BONE health
Abstract

The article "Introduction and Methodology: Standards of Care in Diabetes—2025" from Diabetes Care discusses the importance of continuous medical care for diabetes, emphasizing self-management education and support. The American Diabetes Association's "Standards of Care" provides comprehensive guidelines for clinicians, researchers, and policymakers to improve diabetes outcomes across diverse populations. The document covers screening, diagnosis, and management of diabetes and its complications, with recommendations for various age groups and types of diabetes. The Standards of Care undergoes annual updates based on new evidence and expert recommendations, ensuring its relevance and reliability for healthcare professionals and individuals with diabetes. [Extracted from the article]

Published
2025
Full Text
View/download PDF

32. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025.

Author

ElSayed, Nuha A., McCoy, Rozalina G., Aleppo, Grazia, Bajaj, Mandeep, Balapattabi, Kirthikaa, Beverly, Elizabeth A., Briggs Early, Kathaleen, Bruemmer, Dennis, Cusi, Kenneth, Echouffo-Tcheugui, Justin B., Ekhlaspour, Laya, Fleming, Talya K., Garg, Rajesh, Khunti, Kamlesh, Lal, Rayhan, Levin, Seymour R., Lingvay, Ildiko, Matfin, Glenn, Napoli, Nicola, and Pandya, Naushira

Subjects
MEDICAL personnel, MEDICAL care, MEDICAL education, TYPE 2 diabetes, RESPIRATORY diseases, INTERPROFESSIONAL education, DENTISTS, NUTRITIONISTS
Abstract

The article "Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025" from Diabetes Care presents the American Diabetes Association's clinical practice recommendations for diabetes care, focusing on person-centered collaborative care and involving an interprofessional team. It offers detailed guidance on communication, assessment, and management of diabetes, including lifestyle changes, pharmacotherapy, and preventive care. The document also addresses the importance of comprehensive medical evaluations, screening for autoimmune diseases, managing bone health, and receiving immunizations to prevent infectious diseases like COVID-19, hepatitis B, influenza, and pneumonia. Additionally, it discusses various health issues related to diabetes, such as fragility fractures, cognitive impairment, dental care, and obstructive sleep apnea, emphasizing the need for screening, lifestyle modifications, medication management, and interprofessional care to address these concerns effectively. [Extracted from the article]

Published
2025
Full Text
View/download PDF

33. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD)

Author

Cusi, Kenneth, Isaacs, Scott, Barb, Diana, Basu, Rita, Caprio, Sonia, Garvey, W. Timothy, Kashyap, Sangeeta, Mechanick, Jeffrey I., Mouzaki, Marialena, Nadolsky, Karl, Rinella, Mary E., Vos, Miriam B., and Younossi, Zobair

Published
2022
Full Text
View/download PDF

37. LBP-003 Semaglutide achieves resolution of metabolic dysfunction-associated steatohepatitis via modulation of multiple pathogenic pathways: insights from human and animal studies

Author

Jara, Maximilian Kurt, primary, Norlin, Jenny Egecioglu, additional, Kjaer, Mette, additional, Almholt, Kasper, additional, Bendtsen, Kristian, additional, Bugianesi, Elisabetta, additional, Cusi, Kenneth, additional, Galsgaard, Elisabeth, additional, Geybels, Milan, additional, Gluud, Lise Lotte, additional, Harder, Lea Mørch, additional, Loomba, Rohit, additional, Mazzoni, Gianluca, additional, Newsome, Philip N., additional, Nitze, Louise Maymann, additional, Palle, Mads Sundby, additional, Ratziu, Vlad, additional, Sejling, Anne-Sophie, additional, Wong, Vincent Wai-Sun, additional, Anstee, Quentin M., additional, and Knudsen, Lotte Bjerre, additional

Published
2024
Full Text
View/download PDF

38. FRI-218 Cost of inaction for metabolic dysfunction-associated steatohepatitis (MASH): the projected economic burden in the United States

Author

Younossi, Zobair, primary, Lazarus, Jeffrey V., additional, Allen, Alina M., additional, Cusi, Kenneth, additional, Tacke, Frank, additional, Roden, Michael, additional, Schattenberg, Jörn M., additional, Mark, Henry E., additional, Henry, Linda, additional, Nader, Fatema, additional, and Paik, James M., additional

Published
2024
Full Text
View/download PDF

40. WED-248 A four-country modelling study on doubling MASH diagnostic rates by 2027

Author

Lazarus, Jeffrey V, primary, Mark, Henry E, additional, Alazawi, William, additional, Allen, Alina M, additional, Brennan, Paul N, additional, Byrne, Chris D, additional, Castera, Laurent, additional, Caussy, Cyrielle, additional, Cusi, Kenneth, additional, Grajower, Martin M, additional, Mikkelstrup, Morten Faarbæk, additional, Roden, Michael, additional, Tacke, Frank, additional, and Noureddin, Mazen, additional

Published
2024
Full Text
View/download PDF

41. Advancing the global public health agenda for NAFLD: a consensus statement

Author

Lazarus, Jeffrey V., Mark, Henry E., Anstee, Quentin M., Arab, Juan Pablo, Batterham, Rachel L., Castera, Laurent, Cortez-Pinto, Helena, Crespo, Javier, Cusi, Kenneth, Dirac, M. Ashworth, Francque, Sven, George, Jacob, Hagström, Hannes, Huang, Terry T.-K., Ismail, Mona H., Kautz, Achim, Sarin, Shiv Kumar, Loomba, Rohit, Miller, Veronica, Newsome, Philip N., Ninburg, Michael, Ocama, Ponsiano, Ratziu, Vlad, Rinella, Mary, Romero, Diana, Romero-Gómez, Manuel, Schattenberg, Jörn M., Tsochatzis, Emmanuel A., Valenti, Luca, Wong, Vincent Wai-Sun, Yilmaz, Yusuf, Younossi, Zobair M., and Zelber-Sagi, Shira

Published
2022
Full Text
View/download PDF

43. Preparing for the NASH Epidemic: A Call to Action

Author

Kanwal, Fasiha, Shubrook, Jay H., Younossi, Zobair, Natarajan, Yamini, Bugianesi, Elisabetta, Rinella, Mary E., Harrison, Stephen A., Mantzoros, Christos, Pfotenhauer, Kim, Klein, Samuel, Eckel, Robert H., Kruger, Davida, El-Serag, Hashem, and Cusi, Kenneth

Published
2021
Full Text
View/download PDF

44. Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease

Author

Gries, Jacob J, Lazarus, Jeffrey V, Brennan, Paul N, Siddiqui, Mohammad S, Targher, Giovanni, Lang, Chim C, Virani, Salim S, Lavie, Carl J, Isaacs, Scott, Arab, Juan Pablo, Cusi, Kenneth, and Krittanawong, Chayakrit

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a public health threat as it affects approximately 38% of the adult population worldwide, with its prevalence rising in step with that of obesity and type 2 diabetes. Beyond the implications of MASLD for liver health, it is also associated with cardiovascular and vascular dysfunction. Although the many shared risk factors and common metabolic milieu might indicate that cardiovascular disease and MASLD are discrete outcomes from common systemic pathogeneses, a growing body of evidence has identified a potential causal relationship between MASLD and coronary artery disease, which is the leading cause of morbidity and mortality in people with MASLD and all-cause mortality worldwide. This Review takes an interdisciplinary approach, drawing on hepatology, cardiology, endocrinology, and metabolic and internal medicine specialists to help to delineate the intricate interplay between MASLD and coronary artery disease. It sheds light on novel opportunities for targeted interventions and personalised management strategies.

Published
2025
Full Text
View/download PDF

45. Defining comprehensive models of care for NAFLD

Author

Lazarus, Jeffrey V., Anstee, Quentin M., Hagström, Hannes, Cusi, Kenneth, Cortez-Pinto, Helena, Mark, Henry E., Roden, Michael, Tsochatzis, Emmanuel A., Wong, Vincent Wai-Sun, Younossi, Zobair M., Zelber-Sagi, Shira, Romero-Gómez, Manuel, and Schattenberg, Jörn M.

Published
2021
Full Text
View/download PDF

47. Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen.

Author

Sharma, Anu, Godina Leiva, Eddison, Kalavalapalli, Srilaxmi, Lomonaco, Romina, Marangi, Stephen A., Valdez Saenz, Enrique, Gonzalez, Maria A., Ortiz Rocha, Andrea, Cuervo Pardo, Nathaly, Rosenberg, Jens, Bedossa, Pierre, Bril, Fernando, Barb, Diana, and Cusi, Kenneth

Subjects
YOUNG adults, TYPE 2 diabetes, HEPATIC fibrosis, FATTY liver, OLDER people
Abstract

Objective: The objective of this study was to determine the prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) in young compared with older adults. Methods: Individuals (n = 1420) with (63%) and without type 2 diabetes mellitus (T2D; 37%) who attended internal medicine clinics and did not have a known history of MASLD underwent laboratory evaluation and transient elastography to assess for hepatic steatosis and fibrosis. Magnetic resonance elastography and liver biopsy were recommended when indicated. Results: A total of 243 participants were ages <45 years, and 1177 were ages ≥45 years. Obesity, T2D, and metabolic syndrome were highly prevalent in young adults. Frequencies of steatosis and fibrosis were high in young adults (50.2% and 7.5% vs. older adults 52.7% and 9.9%, respectively) and were significantly higher in those with both obesity and T2D (71.1% and 15.7%, respectively; p < 0.01). In young adults, T2D and obesity were the strongest risk factors for hepatic fibrosis (odds ratios 4.33 [95% CI: 1.37–13.68] and 1.16 [95% CI: 1.07–1.25], respectively; p < 0.05). Conclusions: There is a high prevalence of clinically significant hepatic fibrosis in young adults with cardiometabolic risk factors. Up to one in seven young adults with obesity and T2D had clinically significant hepatic fibrosis on elastography. This highlights the need to screen young adults with cardiometabolic risk factors for MASLD for early detection and intervention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

Author

Arab, Juan Pablo, Dirchwolf, Melisa, Álvares-da-Silva, Mário Reis, Barrera, Francisco, Benítez, Carlos, Castellanos-Fernandez, Marlene, Castro-Narro, Graciela, Chavez-Tapia, Norberto, Chiodi, Daniela, Cotrim, Helma, Cusi, Kenneth, de Oliveira, Claudia Pinto Marques Souza, Díaz, Javier, Fassio, Eduardo, Gerona, Solange, Girala, Marcos, Hernandez, Nelia, Marciano, Sebastián, Masson, Walter, Méndez-Sánchez, Nahum, Leite, Nathalie, Lozano, Adelina, Padilla, Martín, Panduro, Arturo, Paraná, Raymundo, Parise, Edison, Perez, Marlene, Poniachik, Jaime, Restrepo, Juan Carlos, Ruf, Andrés, Silva, Marcelo, Tagle, Martín, Tapias, Monica, Torres, Kenia, Vilar-Gomez, Eduardo, Costa Gil, José Eduardo, Gadano, Adrian, and Arrese, Marco

Published
2020
Full Text
View/download PDF

50. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors

Author

Rai, Sudhir Kumar, Bril, Fernando, Hatch, Heather M., Xu, Yiling, Shelton, Laura, Kalavalapalli, Srilaxmi, Click, Arielle, Lee, Douglas, Beecher, Chris, Kirby, Austin, Kong, Kimi, Trevino, Jose, Jha, Abhishek, Jatav, Shashank, Kriti, Kriti, Luthra, Soumya, Garrett, Timothy J., Guingab-Cagmat, Joy, Plant, Daniel, Bose, Prodip, Cusi, Kenneth, Hromas, Robert A., Tischler, Arthur S., Powers, James F., Gupta, Priyanka, Bibb, James, Beuschlein, Felix, Robledo, Mercedes, Calsina, Bruna, Timmers, Henri, Taieb, David, Kroiss, Matthias, Richter, Susan, Langton, Katharina, Eisenhofer, Graeme, Bergeron, Raymond, Jr., Pacak, Karel, Tevosian, Sergei G., and Ghayee, Hans K.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results